marketcap
Facebook
Twitter
Telegram
Report an ErrorAnnual report 2023
added 11-16-2024
GlaxoSmithKline plc Balance Sheet 2011-2024 | GSK
Annual Balance Sheet GlaxoSmithKline plc
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | 16.5 B | -28.1 B | -24.1 B | -18.1 B | -15.5 B | -19.9 B | -17.3 B | -18.2 B | -15.3 B | -15.2 B | ||
Long Term Debt |
- | - | - | 22.5 B | -23.6 B | -20.3 B | -14.3 B | -14.7 B | -15.3 B | -15.8 B | -15.5 B | -14.7 B | -12.2 B |
Long Term Debt Current |
156 M | 167 M | 203 M | 230 M | 240 M | 24 M | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 37.5 B | -37.3 B | -31.9 B | -26.3 B | -35.1 B | -31.2 B | -22.4 B | -20.6 B | -20.9 B | -17.2 B |
Total Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
46.2 B | 50 B | 57.8 B | 59.6 B | 61.3 B | 54.4 B | -52.9 B | -54.1 B | -44.6 B | -35.7 B | -34.3 B | -34.7 B | -32.3 B |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | - | 6.76 B | 4.53 B | -2.14 B | -6.48 B | -5.39 B | -1.4 B | -2.07 B | 913 M | 652 M | 3.37 B |
Total Assets |
59 B | 60.1 B | 79.1 B | 80.4 B | 79.7 B | 58.1 B | 56.4 B | 59.1 B | 53.4 B | 40.7 B | 42.1 B | 41.5 B | 41.1 B |
Cash and Cash Equivalents |
2.94 B | 3.72 B | 4.27 B | 6.29 B | 4.71 B | 3.87 B | 3.83 B | 4.9 B | - | - | - | - | - |
Book Value |
12.8 B | 10.1 B | 21.3 B | 20.8 B | 18.4 B | 3.67 B | 109 B | 113 B | 98 B | 76.4 B | 76.4 B | 76.2 B | 73.3 B |
Total Shareholders Equity |
- | - | - | 20.8 B | 18.4 B | 3.67 B | 3.49 B | 4.96 B | 8.88 B | - | - | - | - |
All numbers in GBP currency
Quarterly Balance Sheet GlaxoSmithKline plc
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | 812 M | - | - | - | 887 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 34.1 B | - | - | - | 37.5 B | - | - | - | 37.3 B | - | - | - | 31.9 B | - | - | - | 26.3 B | - | - | - | 35.1 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | 57.8 B | - | - | - | 59.6 B | - | - | - | 61.3 B | - | - | - | 54.4 B | - | - | - | 52.9 B | - | - | - | 54.1 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | - | - | 7.94 B | - | - | - | 6.76 B | - | - | - | 4.53 B | - | - | - | -2.72 B | - | - | - | -6.48 B | - | - | - | -5.39 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | - | - | - | 79.1 B | - | - | - | 80.4 B | - | - | - | 79.7 B | - | - | - | 58.1 B | - | - | - | 56.4 B | - | - | - | 59.1 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | - | - | - | 4.27 B | - | - | - | 6.29 B | - | - | - | 4.71 B | - | - | - | 3.87 B | - | - | - | 3.83 B | - | - | - | 4.9 B | - | - | - | 5.83 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
- | - | - | - | 21.3 B | - | - | - | 20.8 B | - | - | - | 18.4 B | - | - | - | 3.67 B | - | - | - | 3.49 B | - | - | - | 4.96 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | - | - | - | 21.3 B | - | - | - | 20.8 B | - | - | - | 18.4 B | - | - | - | 3.67 B | - | - | - | 3.49 B | - | - | - | 4.96 B | - | - | - | 8.88 B | - | - | - | 4.94 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in GBP currency